References
- Diabetes fact sheet in Korea 2016 [Internet]. Seoul: Korean Diabetes Association [cited 2018 Jun 2]. Available from: http://www.diabetes.or.kr/pro/news/.
- Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005;293:217-28. https://doi.org/10.1001/jama.293.2.217
- Lipsky BA, Weigelt JA, Sun X, Johannes RS, Derby KG, Tabak YP. Developing and validating a risk score for lower-extremity amputation in patients hospitalized for a diabetic foot infection. Diabetes Care. 2011;34:1695-700. https://doi.org/10.2337/dc11-0331
- Yoon HS, Choi WJ, Sung IH, Lee HS, Chung HJ, Lee JW. Effects of beraprost sodium on subjective symptoms in diabetic patients with peripheral arterial disease. Clin Orthop Surg. 2013;5:145-51. https://doi.org/10.4055/cios.2013.5.2.145
- Demolis JL, Robert A, Mouren M, Funck-Brentano C, Jaillon P. Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers. J Cardiovasc Pharmacol. 1993;22:711-6. https://doi.org/10.1097/00005344-199311000-00007
- Lievre M, Morand S, Besse B, Fiessinger JN, Boissel JP. Oral beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermettente (BERCI) research group. Circulation. 2000;102:426-31. https://doi.org/10.1161/01.CIR.102.4.426
- Nony P, Ffrench P, Girard P, Delair S, Azoulay S, Girre JP, et al. Platelet-aggregation inhibition and hemodynamic effects of beraprost sodium, a new oral prostacyclin derivative: a study in healthy male subjects. Can J Physiol Pharmacol. 1996;74:887-93. https://doi.org/10.1139/y96-088
- Uchikawa T, Murakami T, Furukawa H. Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus. Arzneimittelforschung. 1992;42:322-4.
- Beebe HG, Dawson DL, Cutler BS, Herd JA, Strandness DE Jr, Bortey EB, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med. 1999;159:2041-50. https://doi.org/10.1001/archinte.159.17.2041
- Dawson DL, Cutler BS, Hiatt WR, Hobson RW 2nd, Martin JD, Bortey EB, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109:523-30. https://doi.org/10.1016/S0002-9343(00)00569-6
- Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation. 1998;98:678-86. https://doi.org/10.1161/01.CIR.98.7.678
- Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol. 2006;47:921-9. https://doi.org/10.1016/j.jacc.2005.09.065
- Belch JJ, Bell PR, Creissen D, Dormandy JA, Kester RC, McCollum RD, et al. Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication. Circulation. 1997;95:2298-302. https://doi.org/10.1161/01.CIR.95.9.2298
- Muller-Buhl U, Diehm C, Krais T, Zimmermann R, Morl H, Eckstein HH. Clinical effects of intravenous iloprost in patients with intermittent claudication. Eur J Clin Pharmocol. 1987;33:127-31. https://doi.org/10.1007/BF00544555
- Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation. 1997;96:2782-4. https://doi.org/10.1161/01.CIR.96.9.2782
- Vane JR, Botting RM. Pharmacodynamic profile of prostacyclin. Am J Cardiol. 1995;75:3A-10A. https://doi.org/10.1016/S0002-9149(99)80377-4
- Goya K, Otsuki M, Xu X, Kasayama S. Effects of the prostaglandin I2 analogue, beraprost sodium, on vascular cell adhesion molecule-1 expression in human vascular endothelial cells and circulating vascular cell adhesion molecule-1 level in patients with type 2 diabetes mellitus. Metabolism. 2003;52:192-8. https://doi.org/10.1053/meta.2003.50025
- Galie N, Manes A, Branzi A. Prostanoids for pulmonary arterial hypertension. Am J Respir Med. 2003;2:123-37. https://doi.org/10.1007/BF03256644
- Ueno Y, Koike H, Nakamura Y, Ochi Y, Annoh S, Nishio S. Effects of beraprost sodium, a prostacyclin analogue, on diabetic neuropathy in streptozotocin- induced diabetic rats. Jpn J Pharmacol. 1996;70:177-82. https://doi.org/10.1254/jjp.70.177
- Aso Y, Tayama K, Takanashi K, Inukai T, Takemura Y. Changes in skin blood flow in type 2 diabetes induced by prostacyclin: association with ankle brachial index and plasma throbomodulin levels. Metabolism. 2001;50:568-72. https://doi.org/10.1053/meta.2001.22517